Glofitamab,Obinutuzumab,Tocilizumab
roche
['mantle,(-dismantle)', 'obinu', 'glofitamab', 'lymphoma', 'lymsm']
in heavily pretreated patients with relapsed/refractory mantle cell lymphoma the use of obinutuzumab 7 days before administration of a fixed dosing regimen of glofitamab induced durable treatment responses. #lymsm #ash22 | 
Oncology news and insights from leading researchers and cancer centers.